# OnCo record nct06211764 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06211764/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06211764", "NCT06211764" ;
  schema:name "A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)"@en ;
  schema:alternateName "SunRISe-5"@en ;
  schema:description "A phase 3 trial of Gemcitabine intravesical system (TAR-200), Mitomycin C and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06211764/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06211764> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-04-09" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/bcg-and-intravesical-therapy/> ;
  onco:drugs <https://onco.cc/drugs/tar-200/>, <https://onco.cc/drugs/mitomycin/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> .